Rare NRG1 Fusion - Epidemiology Forecast - 2032

This ‘Rare NRG1 Fusion - Epidemiology Forecast-2032' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geographies Covered

• The United States
• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
• Study Period: 2019-2032

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Rare NRG1 Fusion Understanding

NRG1 (Neuregulin 1) gene fusions are potentially actionable oncogenic drivers that are present in some solid tumors. NRG1 fusions result in ErbB-mediated pathway activation and present a rational therapeutic target. Oncogenic fusions of NRG1 may cause excess accumulation of the NRG1-fusion protein at the cell surface. This causes persistent activation of ErbB receptor tyrosine kinases that drive excess activity in the mTOR and MAPK pathways and promote tumorigenesis. The NRG1 gene encodes ligands for the ERBB2 (HER2)-ERBB3 heterodimeric receptor tyrosine kinase. Gene fusions of NRG1 such as CD74-NRG1 and SLC33A2-NRG1 have been found at low frequency in a wide range of carcinomas including lung, breast, colorectal, ovarian, and pancreatic cancers and with a wide range of fusion partners.

CD74-NRG1 fusion gene has been identified in a portion of invasive mucinous adenocarcinomas (IMA) of the lung. However, the function of the CD74-NRG1 fusion gene in adenocarcinoma pathogenesis and the mechanisms by which it may impart protumorigenic characteristics to cancer stem cells (CSC) is still unclear. A range of NRG1 fusion partners beyond CD74 has been identified, and they also vary among cancer types. In NSCLC, other fusion partners include the SDC4, SLC3A2, and ATP1B1 genes. In other malignancies, the genes SETD4, TSHZ2, and ZMYM2 (ovarian cancer); ADAM9 and COX10-AS1 genes (breast cancer); and CDH1 and VTCN1 genes (pancreatic cancer) are among known fusion partners of NRG1.

Rare NRG1 Fusion Diagnosis

Fusions involving the neuregulin-1 gene (NRG1) were first identified by transcriptome sequencing of lung adenocarcinomas, which revealed fusion of CD74 to NRG1. NRG1-fusion proteins and genes in solid tumors are detected primarily using immunohistochemistry and fluorescence in situ hybridization (FISH) techniques, DNA next-generation sequencing (NGS), and targeted gene fusion panels on RNA. The gold standard for the detection of NRG1 gene fusions is RNA sequencing in comparison with DNA sequencing. Although fluorescence in situ hybridization (FISH) can be used as a pre-screening method for its detection, only genetic sequencing will allow the identification of the gene fusion. RNA-sequencing is associated with higher sensitivity for genetic rearrangements and can increase the detection of NRG1 gene fusions compared with DNA-based methods, which often do not cover the large introns in NRG1.

Epidemiology Perspective

The Rare NRG1 Fusion epidemiology division provides insights about the historical and current Rare NRG1 Fusion patient pool and forecasted trends for seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2021, the total incident case of Rare NRG1 Fusion were 5,733 cases in the 7MM which are expected to grow during the study period, i.e., 2019-2032.

The disease epidemiology covered in the report provides historical as well as forecasted Rare NRG1 Fusion epidemiology [segmented as Total Incident Cases of NRG1 Fusion, Total Stage-specific Cases of NRG1 Fusion, and Total Treated cases of NRG1 Fusion] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Country Wise- Rare NRG1 Fusion Epidemiology

Estimates show that the highest cases of NRG1 Fusion in the 7MM were in the United States, followed by Japan, Germany, France, Italy, the United Kingdom, and Spain in 2021.

 The incident cases include the following cancers; cholangiocarcinoma, pancreatic cancer, renal cell carcinoma, ovarian cancer, NSCLC, breast cancer, bladder cancer, and colorectal cancer.

 In the United States, the total number of incident cases of NRG1 Fusion were 2,122 cases in the year 2021 which are expected to grow during the study period, i.e., 2019-2032.

 In the year 2021, the total incident cases of NRG1 Fusion in EU-5 were highest in Germany which are expected to grow during the study period, i.e., 2019-2032.

 In Japan, the total number of incident cases of NRG1 Fusion was 1,201 cases in the year 2021 which are expected to grow during the study period, i.e., 2019-2032.

 In the US, NSCLC and Breast cancer has the highest number of the NRG1 fusion cases.

 In the US, the total NRG1 fusions metastatic cases (including locally advanced) was 1,076 in the year 2021 which are expected to grow during the study period, i.e., 2019-2032.

Scope of the Report

• The Rare NRG1 Fusion report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The Rare NRG1 Fusion Report and Model provide an overview of the risk factors and global trends of Rare NRG1 Fusion in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom and Japan)
• The report provides insight about the historical and forecasted patient pool of Rare NRG1 Fusion in seven major markets covering the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Rare NRG1 Fusion.
• The report provides the segmentation of the Rare NRG1 Fusion epidemiology by total incident cases in the 7MM.
• The report provides the segmentation of the Rare NRG1 Fusion epidemiology by total stage-specific cases in the 7MM.
• The report provides the segmentation of the Rare NRG1 Fusion epidemiology by total treated cases in the 7MM.

Report Highlights

• 11-Year Forecast of Rare NRG1 Fusion epidemiology
• 7MM Coverage
• Total Incident Cases of Rare NRG1 Fusion
• Total Stage-specific Cases of Rare NRG1 Fusion
• Total Treated Cases of Rare NRG1 Fusion

KOL-Views

The publisher interviews KOL's and SMEs ' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM concerning the patient population of Rare NRG1 Fusion?
• What are the key findings of the Rare NRG1 Fusion epidemiology across the 7MM and which country will have the highest number of patients during the study period (2019-2032)?
• What would be the total number of patients of Rare NRG1 Fusion across the 7MM during the study period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2019-2032)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2019-2032)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Rare NRG1 Fusion?

Reasons to Buy

The Rare NRG1 Fusion Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Rare NRG1 Fusion market
• Quantify patient populations in the global Rare NRG1 Fusion market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the gender that presents the best opportunities for Rare NRG1 Fusion therapeutics in each of the markets covered
• Understand the magnitude of the Rare NRG1 Fusion population by its severity
• The Rare NRG1 Fusion epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Rare NRG1 Fusion Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 11-year forecast period using reputable sources